Comprehensive analysis of CYP2D6 mutations in human cancers

被引：0
|
作者：
Kuchinski, Kennedy [1 ]
Driggers, Julia [1 ]
Vo, Martin [2 ]
Escorcia, Wilber [1 ]
Wetzel, Hanna [1 ]
机构：
[1] Xavier Univ, Cincinnati, OH 45207 USA
[2] Lake Erie Coll Osteopath Med, Erie, PA USA
来源：
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS | 2023年 / 385卷
关键词：
D O I：
10.1124/jpet.122.245260
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
232
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Catalogue of Somatic Mutations in Cancer Database and Structural Modeling Analysis of CYP2D6 Mutations in Human Cancers
    Kuchinski, Kennedy
    King, Nathaniel
    Driggers, Julia
    Lawson, Kylie
    Vo, Martin
    Skrtic, Shayne
    Slattery, Connor
    Lane, Rebecca
    Simone, Emma
    Mills, Stephen A.
    Escorcia, Wilber
    Wetzel, Hanna
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2024, 391 (03): : 441 - 449
  • [2] Influence of donor and recipient genotypes on CYP2D6 phenotype after liver transplantation:: a study of mutations CYP2D6*3 and CYP2D6*4
    Monek, O
    Paintaud, G
    Bechtel, Y
    Miguet, JP
    Mantion, G
    Bechtel, PR
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 54 (01) : 47 - 52
  • [3] Influence of donor and recipient genotypes on CYP2D6 phenotype after liver transplantation: a study of mutations CYP2D6*3 and CYP2D6*4
    O. Monek
    G. Paintaud
    Y. Bechtel
    J. P. Miguet
    G. Mantion
    P. R. Bechtel
    European Journal of Clinical Pharmacology, 1998, 54 : 47 - 52
  • [4] IN VITRO COMPARATIVE INHIBITORY PROFILES OF SEVERAL CYP2D6 INHIBITORS AND METABOLIC CAPABILITIES OF CYP2D6*1, CYP2D6*2, CYP2D6*10, AND CYP2D6*17 ON TRAMADOL METABOLISM
    Nahid, N.
    Kanumuri, S.
    Sharma, A.
    Wang, D.
    Johnson, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S74 - S75
  • [5] Nomenclature for human CYP2D6 alleles
    Daly, AK
    Brockmoller, J
    Broly, F
    Eichelbaum, M
    Evans, WE
    Gonzalez, FJ
    Huang, JD
    Idle, JR
    IngelmanSundberg, M
    Ishizaki, T
    JacqzAigrain, E
    Meyer, UA
    Nebert, DW
    Steen, VM
    Wolf, CR
    Zanger, UM
    PHARMACOGENETICS, 1996, 6 (03): : 193 - 201
  • [6] Analysis of CYP2D6 expression in human lung: Implications for the association between CYP2D6 activity and susceptibility to lung cancer
    Kivisto, KT
    Griese, KU
    Stuven, T
    Fritz, P
    Friedel, G
    Kroemer, HK
    Zanger, UM
    PHARMACOGENETICS, 1997, 7 (04): : 295 - 302
  • [7] Is CYP2D6 phenotype predictable from CYP2D6 genotype?
    Kiss, Adam Ferenc
    Toth, Katalin
    Juhasz, Cintia
    Temesvari, Manna
    Paulik, Jozsef
    Hirka, Gabor
    Monostory, Katalin
    MICROCHEMICAL JOURNAL, 2018, 136 : 209 - 214
  • [8] CYP2D6 and CYP1A1 mutations in the Turkish population
    Aydin, M
    Hatirnaz, O
    Erensoy, N
    Ozbek, U
    CELL BIOCHEMISTRY AND FUNCTION, 2005, 23 (02) : 133 - 135
  • [9] CYP2D6 mutations and therapeutic outcome in schizophrenic patients
    Hamelin, BA
    Dorson, PG
    Pabis, D
    Still, D
    Bouchard, RH
    Pourcher, E
    Rail, J
    Turgeon, J
    Crismon, ML
    PHARMACOTHERAPY, 1999, 19 (09): : 1057 - 1063
  • [10] Assessment of Activity Levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 Genes by Population Pharmacokinetics of Dextromethorphan
    Abduljalil, K.
    Frank, D.
    Gaedigk, A.
    Klaassen, T.
    Tomalik-Scharte, D.
    Jetter, A.
    Jaehde, U.
    Kirchheiner, J.
    Fuhr, U.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 88 (05) : 643 - 651
12345